Bintrafusp alfa
- Generic Name
- Bintrafusp alfa
- Drug Type
- Biotech
- CAS Number
- 1918149-01-5
- Unique Ingredient Identifier
- NW9K8C1JN3
- Background
Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).
Versamune® HPV Shows Promising ctDNA Clearance and Survival Rates in Advanced Cervical Cancer Trial
• Clinical trial data reveals 100% HPV16 ctDNA clearance in patients receiving Versamune® HPV plus chemoradiotherapy, compared to 50% in standard therapy group at 3-4 months follow-up.
• HPV ctDNA clearance strongly correlates with improved 2-year recurrence-free survival, achieving a significant 92.9% versus 30% rate (P = 0.0067).
• Patients receiving five doses of Versamune® HPV with chemoradiotherapy demonstrated impressive 36-month overall survival rate of 100%, highlighting potential therapeutic value.
Combination Immunotherapies Show Promise in Pancreatic Cancer Treatment
• Combining anti-PD-(L)1 antibodies with hyaluronidase enhances tumor growth inhibition by remodeling the stroma and improving drug delivery in pancreatic cancer models.
• Blocking IL-6 in combination with anti-PD-L1 antibodies inhibits tumor volume and increases survival in preclinical pancreatic cancer models, warranting clinical verification.
• Combining CD40 agonists with PD-L1 blockade improves overall survival and promotes anti-tumor immunity in orthotopic pancreatic cancer mouse models.
• Inhibiting the CXCL12/CXCR4 pathway alongside anti-PD-(L)1 therapy modulates immunosuppression and demonstrates synergistic effects in treating pancreatic cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath